Osteoporosis Drug Trends and Forecast
The future of the global osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets. The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe..
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Osteoporosis Drug by Segment
The study includes a forecast for the global osteoporosis drug by drug type, application, and region.Osteoporosis Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:
- Parathyroid Hormone Therapy
- Bisphosphonates
- Calcitonin
- Rankl Inhibitors
- Others
Osteoporosis Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:
- Primary Osteoporosis
- Secondary Osteoporosis
Osteoporosis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Osteoporosis Drug Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies osteoporosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the osteoporosis drug companies profiled in this report include-- Pfizer
- Eli Lily
- F. Hoffmann La Roche
- Merck
- Amgen
- Radius Health
- Teva Pharmaceutical Industries
Osteoporosis Drug Market Insights
The publisher forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.Within this market, primary osteoporosis will remain the larger segment due to surging aging population and growing awareness towards osteoporosis among consumers.
North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.
Features of the Global Osteoporosis Drug Market
- Market Size Estimates: Osteoporosis drug market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Osteoporosis drug market size by drug type, application, and region in terms of value ($B).
- Regional Analysis: Osteoporosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the osteoporosis drug market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the osteoporosis drug market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the osteoporosis drug market size?Answer: The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030.
Q2. What is the growth forecast for osteoporosis drug market?
Answer: The global osteoporosis drug market is expected to grow with a CAGR of 3.2% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the osteoporosis drug market?
Answer: The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.
Q4. What are the major segments for osteoporosis drug market?
Answer: The future of the osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets.
Q5. Who are the key osteoporosis drug market companies?
Answer: Some of the key osteoporosis drug companies are as follows:
- Pfizer
- Eli Lily
- F. Hoffmann La Roche
- Merck
- Amgen
- Radius Health
- Teva Pharmaceutical Industries
Answer: The publisher forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.
Q7. In osteoporosis drug market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, the publisher provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the osteoporosis drug market by drug type (parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others), application (primary osteoporosis and secondary osteoporosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Osteoporosis Drug Market : Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer
- Eli Lily
- F. Hoffmann La Roche
- Merck
- Amgen
- Radius Health
- Teva Pharmaceutical Industries
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
